# Mirabegron exhibits antibacterial and Immunomodulatory activities demonstrated by in vitro and in vivo studies

**Authors:** Esraa A. Ahmed, Ahmed M. Abd-Eldayem

PMC · DOI: 10.1038/s41598-025-23392-2 · 2025-11-07

## TL;DR

Mirabegron, a drug for bladder issues, shows antibacterial and immune-boosting effects in lab and animal tests, suggesting it could help treat urinary tract infections.

## Contribution

Mirabegron's antibacterial and immunomodulatory properties are newly demonstrated in both in vitro and in vivo studies.

## Key findings

- Mirabegron showed significant antibacterial activity, especially against Escherichia coli.
- It increased phagocytic activity and immune molecule levels in infected rats.
- The drug enhanced both innate and acquired immune responses in vivo.

## Abstract

Mirabegron is a beta 3-adrenoceptor agonist that can help with incontinence, dysuria, and bladder overactivity. It alleviates the symptoms of prostate enlargement and urinary tract infections (UTIs) in the elderly. We aimed to explore Mirabegron’s antimicrobial and immune-boosting properties, trying to benefit people suffering from urinary tract infections and having an overactive bladder. Mirabegron’s putative antibacterial activity was investigated using the well diffusion method (In Vitro). Infected rats were treated with mirabegron (10 mg/kg, oral) and used for evaluation of immunomodulatory actions (In Vivo). We tested the antibacterial activity in vitro against numerous bacterial strains, including Escherichia coli (E. coli). The phagocytic activity and survival of peritoneal macrophages were examined. Also, serum levels of immunoglobulin G (IgG), immunoglobulin M (IgM), and interferon-γ (INF-γ) were estimated in E. coli-infected rats. We found that mirabegron exhibited significant antibacterial activity, particularly against E. coli. Phagocytic activity increased notably in vivo, indicating an improved innate immune response. Mirabegron also demonstrated a substantial rise in immunoglobulin and cytokine levels, enhancing acquired immunity. According to our findings, in vitro and in vivo tests of mirabegron revealed possible antibacterial activity as well as immunomodulatory properties. Mirabegron could alleviate symptomatic UTIs.

## Linked entities

- **Chemicals:** Mirabegron (PubChem CID 9865528)
- **Diseases:** overactive bladder (MONDO:0006624)
- **Species:** Escherichia coli (taxon 562)

## Full-text entities

- **Diseases:** incontinence (MESH:D014549), dysuria (MESH:D053159), bladder overactivity (MESH:D053201), prostate enlargement (MESH:D011472), UTIs (MESH:D014552)
- **Chemicals:** Mirabegron (MESH:C520025)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Escherichia coli (E. coli, species) [taxon 562]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12594953/full.md

---
Source: https://tomesphere.com/paper/PMC12594953